- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT03254836
Sleep and Survival in Colorectal Cancer
Sleep-wake Rhythm in the Perioperative Period in Patients Admitted for Elective Radical Surgery for Colorectal Cancer: an Observational Prospective Cohort Study.
Objective The objective of the current trial is to investigate the effect of perioperative sleep and circadian rhythm on the natural course of survival among patient diagnosed with colorectal cancer. Concurrently, outcome measures like depression, fatigue, quality of life, and co-morbidity will be measured continuously in the short-, intermediate- and long-term period following diagnosis.
The a-priori hypothesis is that preoperative sleep and circadian disturbances is a prognostic marker of reduced overall survival. Likewise, preoperative sleep-wake disturbances at baseline are expected to result in overall universally reduced quality of life, increased depression and fatigue. Furthermore, development of sleep-wake disturbances in the postoperative period as compared to preoperative sleep-wake rhythm is expected to a prognostic marker of negative outcomes.
Target and study population The study population are all patients diagnosed with colorectal cancer in Region Zealand recruited consecutively from the trial initiation until study end each patient with an intended 5 year follow-up period. All available cases will be included in the trial.
Study design The study will be an observational prospective cohort study applying a longituditional repeated measure design.
Exposures and outcomes of interest The primary outcomes in the trial are sleep and circadian outcomes measured via actigraphy in the perioperative period.
Furthermore, cancer related survival and overall survival in the 5 year follow-up period is considered primary outcomes.
Secondary outcomes consist of consecutively measured depression, fatigue, quality of life, follow-up treatment and co-morbidity.
Exposure variables are primary related to the cancer, i.e. cancer stage, surgical treatment, oncological treatment, baseline co-morbidity and pharmacological treatment. Some of the secondary outcomes could be expected to serve as confounding or mediating factors.
Meaningful control for confounding will in the analysis phase be cancer stage and baseline sleep-wake rhythm status.
Sampling methods All available cases will be sought included in the trial. No formal sample size has been performed and continues inclusion into the trial will be performed during an 1,5 year period.
Statistical analyses The relationship between overall survival and baseline sleep-wake rhythm will be investigated using survival statistics and/or multivariate logistic regression.
Expected results The investigators expect to see a marked difference in overall survival among patients with sleep and circadian disturbances at baseline.
Tutkimuksen yleiskatsaus
Tila
Interventio / Hoito
Opintotyyppi
Ilmoittautuminen (Todellinen)
Yhteystiedot ja paikat
Opiskelupaikat
-
-
Zealand
-
Roskilde, Zealand, Tanska, 4000
- Department of Surgery, Zealand University Hospital
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Näytteenottomenetelmä
Tutkimusväestö
Kuvaus
Inclusion Criteria:
- Diagnosis of colorectal cancer as determined at the multi-disciplinary team conference.
- Admitted to elective radical surgery at the department of surgery at Zealand University Hospital
- Age above 18 years
- Informed consent
Exclusion Criteria:
- Non-ability to complete the study as assessed by the investigator
- Non-fluent in Danish.
- History of cognitive impairment (e.g. dementia)
- Paralysis or inability to answer study questioners electronically.
- Stadium 4 colonic adenocarcinoma with no surgical treatment options as determined at the multi-disciplinary conference.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
Kohortit ja interventiot
Ryhmä/Kohortti |
Interventio / Hoito |
---|---|
Colorectal cancer undergoing elective surgery
All patients eligible for elective curative intended surgery for colonic adenocarcinoma at Zealand University Hospital. Patients will recieve treatment as per standard of care. |
Elective radical surgery for adenocarcinoma.
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Actigraphy
Aikaikkuna: Approximately 1 week preoperatively to 2 weeks postoperatively
|
Assessment of activity using accelerometor - Sleep and circadian assesment.
|
Approximately 1 week preoperatively to 2 weeks postoperatively
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Major Depression Inventory
Aikaikkuna: Baseline (approx. 1 week preoperatively), 2 weeks postoperatively, 3 months postoperatively, 6 months postoperatively, 12 months postoperativly, 24 months postoperatively, 36 months postoperatively, 60 months postoperatively.
|
Assesment of depression
|
Baseline (approx. 1 week preoperatively), 2 weeks postoperatively, 3 months postoperatively, 6 months postoperatively, 12 months postoperativly, 24 months postoperatively, 36 months postoperatively, 60 months postoperatively.
|
Insomnia Severity Index
Aikaikkuna: Baseline (approx. 1 week preoperatively), 2 weeks postoperatively, 3 months postoperatively, 6 months postoperatively, 12 months postoperativly, 24 months postoperatively, 36 months postoperatively, 60 months postoperatively.
|
Subjective sleep assesment
|
Baseline (approx. 1 week preoperatively), 2 weeks postoperatively, 3 months postoperatively, 6 months postoperatively, 12 months postoperativly, 24 months postoperatively, 36 months postoperatively, 60 months postoperatively.
|
Quality of life assesment
Aikaikkuna: Baseline (approx. 1 week preoperatively), 2 weeks postoperatively, 3 months postoperatively, 6 months postoperatively, 12 months postoperativly, 24 months postoperatively, 36 months postoperatively, 60 months postoperatively.
|
EORCT-QLQ-C30
|
Baseline (approx. 1 week preoperatively), 2 weeks postoperatively, 3 months postoperatively, 6 months postoperatively, 12 months postoperativly, 24 months postoperatively, 36 months postoperatively, 60 months postoperatively.
|
Quality of life assesment
Aikaikkuna: Baseline (approx. 1 week preoperatively), 2 weeks postoperatively, 3 months postoperatively, 6 months postoperatively, 12 months postoperativly, 24 months postoperatively, 36 months postoperatively, 60 months postoperatively.
|
EORCT-QLQ-CR29
|
Baseline (approx. 1 week preoperatively), 2 weeks postoperatively, 3 months postoperatively, 6 months postoperatively, 12 months postoperativly, 24 months postoperatively, 36 months postoperatively, 60 months postoperatively.
|
Mortality
Aikaikkuna: Baseline (approx. 1 week preoperatively), 2 weeks postoperatively, 3 months postoperatively, 6 months postoperatively, 12 months postoperativly, 24 months postoperatively, 36 months postoperatively, 60 months postoperatively.
|
Baseline registration and follow-up assessments
|
Baseline (approx. 1 week preoperatively), 2 weeks postoperatively, 3 months postoperatively, 6 months postoperatively, 12 months postoperativly, 24 months postoperatively, 36 months postoperatively, 60 months postoperatively.
|
Co-morbidity
Aikaikkuna: Baseline (approx. 1 week preoperatively), 2 weeks postoperatively, 3 months postoperatively, 6 months postoperatively, 12 months postoperativly, 24 months postoperatively, 36 months postoperatively, 60 months postoperatively.
|
Baseline registration and follow-up assessments
|
Baseline (approx. 1 week preoperatively), 2 weeks postoperatively, 3 months postoperatively, 6 months postoperatively, 12 months postoperativly, 24 months postoperatively, 36 months postoperatively, 60 months postoperatively.
|
Drug prescription history (Drug name and dosage)
Aikaikkuna: Baseline (approx. 1 week preoperatively), 2 weeks postoperatively, 3 months postoperatively, 6 months postoperatively, 12 months postoperativly, 24 months postoperatively, 36 months postoperatively, 60 months postoperatively.
|
Baseline registration and follow-up assessments
|
Baseline (approx. 1 week preoperatively), 2 weeks postoperatively, 3 months postoperatively, 6 months postoperatively, 12 months postoperativly, 24 months postoperatively, 36 months postoperatively, 60 months postoperatively.
|
Follow-up cancer treatment (Adjuvant chemotherapy, timing and duration)
Aikaikkuna: Baseline (approx. 1 week preoperatively), 2 weeks postoperatively, 3 months postoperatively, 6 months postoperatively, 12 months postoperativly, 24 months postoperatively, 36 months postoperatively, 60 months postoperatively.
|
Baseline registration and follow-up assessments
|
Baseline (approx. 1 week preoperatively), 2 weeks postoperatively, 3 months postoperatively, 6 months postoperatively, 12 months postoperativly, 24 months postoperatively, 36 months postoperatively, 60 months postoperatively.
|
Yhteistyökumppanit ja tutkijat
Sponsori
Tutkijat
- Päätutkija: Michael T Madsen, M.D., Department of Surgery, Zealand University Hospital
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Todellinen)
Opintojen valmistuminen (Odotettu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
- Käyttäytymisoireet
- Mielenterveyshäiriöt
- Ruoansulatuskanavan sairaudet
- Hermoston sairaudet
- Neoplasmat
- Dyssomniat
- Neoplasmat sivustoittain
- Neurologiset ilmenemismuodot
- Ruoansulatuskanavan kasvaimet
- Ruoansulatuskanavan kasvaimet
- Ruoansulatuskanavan sairaudet
- Paksusuolen sairaudet
- Suoliston sairaudet
- Ammattitaudit
- Suoliston kasvaimet
- Peräsuolen sairaudet
- Kronobiologiset häiriöt
- Masennus
- Uniherätyshäiriöt
- Kolorektaaliset kasvaimet
- Unihäiriöt, vuorokausirytmi
Muut tutkimustunnusnumerot
- MTM-V3
- SJ-600 (Muu tunniste: Region Zealand ethics Comittee)
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
IPD-suunnitelman kuvaus
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .
Kliiniset tutkimukset Standard of care
-
Rhizen Pharmaceuticals SAIncozen Therapeutics Pvt LtdValmis
-
HeNan Sincere Biotech Co., LtdTuntematon
-
The Cleveland ClinicSanten Inc.Aktiivinen, ei rekrytointi
-
PfizerAktiivinen, ei rekrytointiHemofilia A | Hemofilia BYhdysvallat, Kanada, Espanja, Australia, Korean tasavalta, Taiwan, Brasilia, Italia, Japani, Turkki, Saksa, Yhdistynyt kuningaskunta, Saudi-Arabia, Ranska, Ruotsi, Belgia, Kreikka, Israel
-
Maureen LyonAmerican Cancer Society, Inc.Valmis
-
RWTH Aachen UniversityBiotestRekrytointiSepsis | Septinen shokki | PeritoniittiItävalta, Saksa
-
Celleration, Inc.LopetettuDiabeettinen jalkahaavaYhdysvallat
-
Brian W. NoehrenU.S. Army Medical Research and Development CommandRekrytointiReisiluun murtuma | Sääriluun murtumatYhdysvallat
-
University of FloridaPatient-Centered Outcomes Research InstituteAktiivinen, ei rekrytointiEturauhassyöpäYhdysvallat